In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Tenaya Therapeutics (TNYA – Research Report). The company’s shares opened today at $4.25.
Baral covers the Healthcare sector, focusing on stocks such as Neurogene, Milestone Pharmaceuticals, and Insmed. According to TipRanks, Baral has an average return of 6.9% and a 43.06% success rate on recommended stocks.
Currently, the analyst consensus on Tenaya Therapeutics is a Strong Buy with an average price target of $20.00, implying a 370.59% upside from current levels. In a report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $18.00 price target.
TNYA market cap is currently $333.7M and has a P/E ratio of -2.52.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Tenaya Therapeutics (TNYA) Company Description:
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration, and precision medicine.
Read More on TNYA:
- Tenaya Therapeutics reports Q1 EPS (40c), consensus (42c)
- Tenaya Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
- Tenaya Therapeutics to Highlight Growing Capabilities in Capsid Engineering, Gene Editing and Manufacturing at the American Society of Gene and Cell Therapy 27th Annual Meeting
- Tenaya Therapeutics price target lowered to $18 from $19 at Canaccord
- Tenaya Therapeutics’ Financial Tightrope: Balancing Development Costs with Cash Reserves
